VASCOR Imidapril Hydrochloride 10mg Tablet 1's
RXDRUG-DRP-XY23799-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Vascor
Full Details
Dosage Strength
10mg
Drug Ingredients
- Imidapril
Drug Packaging
Tablet 1's
Generic Name
Imidapril Hydrochloride
Dosage Form
Tablet
Registration Number
DRP-XY23799
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Treatment of hypertension.
Dosage/Direction for Use
Initial Dose: 5-10 mg once daily in hypertensive patients with normal renal function. Doses can be increased up to 20 mg according to patient response. The dosage should be reduced in patients with renal insufficiency, renal hypertension or severe hypertension. Or as prescribed by the physician.
Administration
Should be taken on an empty stomach: Take 15 min before meals. However, when initiating therapy, 1st dose should be given at bedtime.
Contraindications
Patients with known hypersensitivity to ACE inhibitors or with a history of angioneurotic edema.
Warnings
Use in pregnancy: Imidapril, like any other ACE inhibitors, should not be given during pregnancy as it may cause fetal/neonatal morbidity or mortality. Discontinue use of imidapril once pregnancy is detected. Fetal exposure to ACE inhibitors can cause hypotension, renal failure, anuria, skull hypoplasia or even death in the newborn. Maternal oligohydramnios has been reported, presumably resulting from decreased fetal renal function. Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In these patients, it is advised to use a different type of dialysis membrane or a different class of antihypertensive agent.
Special Precautions
Administer with caution in the elderly and in patients with renal disease. Increased age and impaired renal function may decrease the urinary excretion of imidapril and its metabolites.
Imidapril should be used with caution in patients with unilateral or bilateral renal artery stenosis since increase in blood urea nitrogen and serum creatinine may occur.
In general, ACE inhibitors should be used with caution in patients with sodium depletion or hypovolemia and those undergoing dialysis, major surgery or during anesthesia since severe hypotension may occur.
Use in lactation: Imidapril is excreted in breast milk therefore, avoid use of the drug in nursing mothers.
Imidapril should be used with caution in patients with unilateral or bilateral renal artery stenosis since increase in blood urea nitrogen and serum creatinine may occur.
In general, ACE inhibitors should be used with caution in patients with sodium depletion or hypovolemia and those undergoing dialysis, major surgery or during anesthesia since severe hypotension may occur.
Use in lactation: Imidapril is excreted in breast milk therefore, avoid use of the drug in nursing mothers.
Use In Pregnancy & Lactation
Use in pregnancy: Imidapril, like any other ACE inhibitors, should not be given during pregnancy as it may cause fetal/neonatal morbidity or mortality. Discontinue use of imidapril once pregnancy is detected. Fetal exposure to ACE inhibitors can cause hypotension, renal failure, anuria, skull hypoplasia or even death in the newborn. Maternal oligohydramnios has been reported, presumably resulting from decreased fetal renal function. Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In these patients, it is advised to use a different type of dialysis membrane or a different class of antihypertensive agent.
Use in lactation: Imidapril is excreted in breast milk therefore, avoid use of the drug in nursing mothers.
Use in lactation: Imidapril is excreted in breast milk therefore, avoid use of the drug in nursing mothers.
Adverse Reactions
Imidapril is well-tolerated. Adverse reactions are usually mild and transient. The most frequent adverse reactions include dry cough (2.8%), discomfort in the throat (0.5%), palpitation (0.2%), headache (0.2%) and rash (0.2%). The following adverse effects occurred rarely (0.1% each) and include fatigue, dizziness, hot flush, diarrhea, nausea and vomiting.
Abnormal laboratory test values were observed in 5.6% (47/832) of patients but none is considered related to imidapril treatment.
Abnormal laboratory test values were observed in 5.6% (47/832) of patients but none is considered related to imidapril treatment.
Drug Interactions
Combination of imidapril with other antihypertensive drugs eg, diuretics, β-blockers and other vasodilators, potentiates the drug's hypotensive effects. Co-administration of imidapril and rifampicin decreases hypotensive effect of imidapril due to decrease in plasma level of imidaprilat. Concomitant administration of imidapril with potassium-sparing diuretics (ie, amiloride, spironolactone or triamterene), potassium supplements or potassium-sparing salt substitutes may lead to hyperkalemia.
Lithium toxicity has been reported in patients receiving lithium concomitantly with ACE inhibitors.
Lithium toxicity has been reported in patients receiving lithium concomitantly with ACE inhibitors.
Storage
Store at temperatures not more than 30°C.
Action
Angiotensin-converting enzyme inhibitor/antihypertensive.
Pharmacology: Imidapril is an ester prodrug which is hydrolyzed after absorption to imidaprilat, the active metabolite. Imidaprilat has potent angiotensin-converting enzyme (ACE) inhibitory effects, 1.2 and 2.6 times that of enalaprilat and captopril, respectively.
The hypotensive effect of imidapril is mainly due to ACE inhibition and the consequent reduction in angiotensin II, resulting in dilatation of peripheral vessels and reduction in vascular resistance. The hypotensive effect of imidapril is comparable to enalapril and 5-10 times more potent than that of captopril.
Imidapril decreases total peripheral vascular resistance without increase in heart rate or cardiac contractility. Imidapril increases renal blood flow and reduces renal vascular resistance mainly due to dilatation of the efferent arteriole. It showed no specific effect on the CNS, digestive, respiratory, smooth muscle, reproductive, urologic, hematologic and metabolic systems.
Pharmacokinetics: About 25-40% of imidapril is absorbed after oral administration. Imidapril undergoes deesterification in the liver to form imidaprilat. Peak plasma concentrations of imidaprilat are reached within 6-8 hrs after single oral doses of 2.5-20 mg of imidapril, and decline slowly with a t½ of 7-9 hrs. Imidapril and imidaprilat were shown to be about 85% and 51% protein bound, respectively.
Drug elimination is primarily via the renal (40%) and hepatobiliary (50%) routes. Increased age and impaired renal function may decrease the urinary excretion of imidapril and its metabolites.
Pharmacology: Imidapril is an ester prodrug which is hydrolyzed after absorption to imidaprilat, the active metabolite. Imidaprilat has potent angiotensin-converting enzyme (ACE) inhibitory effects, 1.2 and 2.6 times that of enalaprilat and captopril, respectively.
The hypotensive effect of imidapril is mainly due to ACE inhibition and the consequent reduction in angiotensin II, resulting in dilatation of peripheral vessels and reduction in vascular resistance. The hypotensive effect of imidapril is comparable to enalapril and 5-10 times more potent than that of captopril.
Imidapril decreases total peripheral vascular resistance without increase in heart rate or cardiac contractility. Imidapril increases renal blood flow and reduces renal vascular resistance mainly due to dilatation of the efferent arteriole. It showed no specific effect on the CNS, digestive, respiratory, smooth muscle, reproductive, urologic, hematologic and metabolic systems.
Pharmacokinetics: About 25-40% of imidapril is absorbed after oral administration. Imidapril undergoes deesterification in the liver to form imidaprilat. Peak plasma concentrations of imidaprilat are reached within 6-8 hrs after single oral doses of 2.5-20 mg of imidapril, and decline slowly with a t½ of 7-9 hrs. Imidapril and imidaprilat were shown to be about 85% and 51% protein bound, respectively.
Drug elimination is primarily via the renal (40%) and hepatobiliary (50%) routes. Increased age and impaired renal function may decrease the urinary excretion of imidapril and its metabolites.
MedsGo Class
ACE Inhibitors/Direct Renin Inhibitors
Please sign in so that we can notify you about a reply